Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01751425
Title Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center|Incyte Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.